2020 Second Quarter Conference Call

July 28, 2020 • 8:30 AM ET

Jul 28, 2020 • 7:00 AM EDT

Q2 2020 Quarterly Results

Quarter Ended Jun 30, 2020

Consolidated revenue decreased 14% to $87 million

Clinical Services revenue decreased 17% to $74 million

Pharma Services revenue increased 3% to $13 million

Pharma Services backlog increased 63% to $173 million

NeoGenomics to Build State-of-the-Art Oncology Laboratory and Global Headquarters in Fort Myers, Florida

NeoGenomics Announces New $250 Million Credit Agreement

NeoGenomics and QIAGEN Collaborate to Offer Companion Diagnostic Test for HR+/HER2 - Advanced Breast Cancer Patients to Detect a PIK3CA Mutation

Company Profile

NeoGenomics, Inc. specializes in cancer genetic testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services division serves pharmaceutical clients in clinical trials and drug development.   Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Latest 10-K

View Latest 10-K

NeoGenomics, Inc.

Nasdaq: NEO

Market/Symbol

Price

Change

Volume

Day Range

52 week Range

IR Contact Information

Investor Relations William Bonello
Chief Strategy and Corporate Development Officer
Director, Investor Relations
T: (239) 690-4238
M: (239) 284-4314
bill.bonello@neogenomics.com

Transfer Agent Standard Registrar & Transfer Company
12528 South 1840 East
Draper, UT 84020
T: (801) 571-8844